Adjuvant capecitabine in combination with docetaxel and cyclophosphamide versus anthracycline plus docetaxel and cyclophosphamide regimen in women with high‐risk, HER2‐negative breast cancer: An open‐label, randomized controlled trial

Abstract Background The standard adjuvant chemotherapy for early‐stage, high‐risk breast cancer includes anthracyclines and taxanes. While anthracycline‐based regimens have proven effective in human epidermal growth factor receptor 2 (HER2)‐positive breast cancer, their efficacy may be reduced in HE...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Yu Song, Yingjiao Wang, Xi Cao, Ying Xu, Yidong Zhou, Qiang Sun, Songjie Shen
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2025-09-01
Edice:	Cancer Communications
Témata:	adjuvant chemotherapy capecitabine disease‐free survival her2‐negative breast cancer overall survival
On-line přístup:	https://doi.org/10.1002/cac2.70041
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!